Government agencies and non-profits at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
63 government agencies and non-profits are at ASH 2026 — 12 presentations on the program and 51 with a booth in the exhibit hall. Most represented: Versiti (3 on the program), National Heart, Lung, and Blood Institute (2 on the program), Veterans Health Administration (2 on the program). 54 of them have their own page in this guide. As of Sep 27, 2026.
Topic
Top represented
Showing 1–15 of 63 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Versiti Milwaukee, WI | |
Nonprofit blood health organization in Milwaukee operating blood centers, specialty diagnostic laboratories and the Blood Research Institute. | Talk Molecular Mechanisms of Trm Maintenance, Activation, and Proliferation Signaling proteins of the common gamma chain family work together to keep tissue-resident memory T cells self-renewing, suggesting cytokine-based treatments. Session The Big Clot Problem Risk grading of pulmonary embolism, clot-dissolving and catheter treatments for large vein clots, and preventing long-term leg damage after deep vein thrombosis. |
National Heart, Lung, and Blood Institute Bethesda, MD | |
NIH institute that funds and conducts research on heart, lung, blood and sleep disorders, including sickle cell disease. | Talk Clonal Selection of Somatic Mutations in Immune Mediated BMF How acquired mutations are selected in immune and inherited bone marrow failure, and how genomic tests can track clones that progress to myeloid cancer. |
Veterans Health Administration Washington, DC | |
US Department of Veterans Affairs health system, running VA medical centers and clinics nationwide and recruiting clinicians. | Booth Exhibiting at Booth 2819 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
New York Blood Center Rye, NY | |
Nonprofit network of community blood centers supplying blood products to hospitals, with research programs in transfusion medicine and hematology. | |
CLL Society Chula Vista, CA | |
Non-profit for people with CLL and SLL, providing patient education, advocacy, support and research grants, plus free materials for clinicians. | Booth Exhibiting at Booth 2914 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. |
Biotechnology Innovation Organization Washington, DC | |
Trade association representing biotechnology companies and research organizations; advocates on policy and runs the annual BIO convention. | |
Inserm Paris, France | |
France's national public institute for health and medical research, running research units across universities and hospitals. | Talk Sticky Surfaces: Mechanistic Insights Into Macrovascular Clot Formation How clots form in large arteries, fibrin's role in halting clot growth, and new artery-mimicking and mouse models for testing stent thrombosis. |
Istituto per lo Studio, la Prevenzione e la Rete Oncologica Florence, Italy | |
Public institute of Tuscany's regional health service for cancer prevention, screening, research and coordination of the regional oncology network. | Symposium Fri Dec 11 7:00am–10:00am From Controversies to Consensus in Paroxysmal Nocturnal Hemoglobinuria: Developing IPIG Guidelines Expert consensus on paroxysmal nocturnal hemoglobinuria, debating disease types, anticoagulation, and breakthrough hemolysis on complement inhibitors. |
National Cancer Institute Bethesda, MD | |
US federal agency within the National Institutes of Health that leads national cancer research and training. | Talk Novel Approaches for Diffuse Large B-Cell Lymphoma Where antibody-drug conjugates and other approved targeted drugs fit in diffuse large B-cell lymphoma care, and experimental combinations to overcome resistance. |
National Institutes of Health Bethesda, MD | |
US federal medical research agency that funds and conducts biomedical research through its institutes and centers. | Symposium Fri Dec 11 7:00am–10:00am From Controversies to Consensus in Paroxysmal Nocturnal Hemoglobinuria: Developing IPIG Guidelines Expert consensus on paroxysmal nocturnal hemoglobinuria, debating disease types, anticoagulation, and breakthrough hemolysis on complement inhibitors. |
Sanquin Amsterdam, Netherlands | |
Dutch non-profit blood supply organization that collects blood and plasma and runs transfusion research. | Session Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders Blood-clotting disorders driven by antibodies to platelet factor 4, including heparin- and vaccine-induced forms, compared on causes, diagnosis, and treatment. |
Scottish National Blood Transfusion Service Edinburgh, United Kingdom | |
Scotland's national blood service, supplying blood, tissues and cells and running transfusion research. | Talk Clinical Translation of Lab-Grown Red Blood Cells: First-in-Human Studies and Early Outcomes Early human trials of lab-grown red blood cells, covering their safety, survival in circulation, manufacturing consistency, and regulatory path to transfusion. |
HealthTree Foundation South Jordan, UT | |
Patient nonprofit whose free health record app gathers blood cancer patients' data to match them with trials, education and support, and power research. | Booth Exhibiting at Booth 2924 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms CAR-T as standard lymphoma care and what comes next, including dual-target, faster-manufactured, and in vivo versions that could widen patient access. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. |
MDS Foundation New York, NY | |
Nonprofit advocacy group raising awareness of myelodysplastic syndromes and supporting patients, families and clinicians in MDS and AML. | Booth Exhibiting at Booth 2515 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. |
National Comprehensive Cancer Network Plymouth Meeting, PA | |
Nonprofit alliance of cancer centers that publishes the NCCN clinical practice guidelines and provides clinician and patient education. | Booth Exhibiting at Booth 2513 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. |
Instantly find 20 buyers from government agencies and non-profits
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction